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Abstract
 
Previous studies suggest that the diversity of the expressed variable (V) region repertoire of the
immunoglobulin (Ig)H chain of B-CLL cells is restricted. Although limited examples of
marked constraint in the primary structure of the H and L chain V regions exist, the possibility
that this level of restriction is a general principle in this disease has not been accepted. This report
describes five sets of patients, mostly with unmutated or minimally mutated 
 
IgV
 
 genes, with
strikingly similar B cell antigen receptors (BCRs) arising from the use of common H and L
chain V region gene segments that share CDR3 structural features such as length, amino acid
composition, and unique amino acid residues at recombination junctions. Thus, a much more
striking degree of structural restriction of the entire BCR and a much higher frequency of receptor
sharing exists among patients than appreciated previously. The data imply that either a significant
fraction of B-CLL cells was selected by a limited set of antigenic epitopes at some point in their
development and/or that they derive from a distinct B cell subpopulation with limited Ig V region
diversity. These shared, stereotyped Ig molecules may be valuable probes for antigen identifica-
tion and important targets for cross-reactive idiotypic therapy.
Key words: Ig variable region genes • human • B lymphocytes • antibodies • autoantibodies
 
Introduction
 
The B lymphocyte clone expanded in chronic lymphocytic
leukemia (B-CLL) expresses low levels of surface membrane
Ig, the B cell antigen receptor (BCR). The genetics of this
Ig have clinical relevance, as patients with a clone whose Ig
variable (V) region has no or few mutations have a signifi-
cantly worse outcome than those with significant numbers
of Ig V mutations (1, 2). The biology underlying this asso-
ciation is unclear.
Several lines of evidence support a role for the BCR in
the evolution of B-CLL (for review see reference 3). The
distribution of individual 
 
IgV
 
H
 
 in B-CLL clones differs
from that found in normal cells (4), with an increased fre-
quency of 
 
V
 
H
 
1-69, 
 
V
 
H
 
4-34, and 
 
V
 
H
 
3-07 (4–6). In addition,
the distribution of mutations among B-CLL cases using
these specific V
 
H
 
 genes is selectively biased (4, 5, 7).
Recently, two subgroups of B-CLL cases with remark-
able similarity of the entire BCR (V regions of the H and L
chains) were identified (8, 9). Although these findings are
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provocative, they have been considered rare and potentially
anomalous because, in one instance, the clones expressed
IgG (9) and in the other geography and ethnicity may be
relevant (10). This report describes another five groups of
B-CLL patients that express BCRs of strikingly similar pri-
mary structure defined by highly similar Ig V regions in the
H and L chains, and, in particular, distinct H and L CDR3
configurations. Thus, a significant fraction of B-CLL clones
derive from B lymphocytes with constrained antigen-bind-
ing sites that could recognize individual, discrete antigens
or classes of structurally similar epitopes.
 
Materials and Methods
 
IgV Gene Sequencing. 
 
V
 
H
 
DJ
 
H
 
 and V
 
L
 
J
 
L
 
 sequences were deter-
mined by previously described methods (4, 9).
 
Database Searches. 
 
B-CLL Ig H chain V sequences from our
collection (
 
n
 
 
 
  
 
255) and the public databases (
 
n
 
 
 
  
 
197) were
subjected to BLAST searches of both nucleotide and protein da-
tabases to identify similar sequences. The criteria used to define
“sets” of similar rearranged V
 
H
 
DJ
 
H
 
 were as follows: (a) use of the
same V
 
H
 
, D, and J
 
H
 
 germline genes; (b) use of the same D seg-
ment reading frame and position relative to the V
 
H
 
, plus or minus
one codon; and (c) an amino acid similarity within the HCDR3
of 
 
 
 
60% identity. In addition, all B-CLL Ig H protein sequences
were aligned and clustered using the ClustalW alignment algo-
rithm. Sequences clustering tightly were visually inspected for
similarity. All of these searches used the complete V
 
H
 
DJ
 
H
 
 and as
such were weighted toward sequences that used the same V
 
H
 
gene. To identify sequences with similar HCDR3 but different
V
 
H
 
 genes, CDR3 motifs from the various sets were used to search
the public databases with the ProteinInfo search engine (http://
prowl.rockefeller.edu). The criteria for the members of set V
were altered to permit the use of different 
 
IgV
 
H
 
 genes that were
members of the same 
 
IgV
 
H
 
 clan, while retaining the criteria for
the rearranged V
 
L
 
J
 
L
 
. Use of the same specific 
 
IgV
 
L
 
 gene and
 
 
 
85% LCDR3 identity was required for the inclusion of a com-
panion rearranged V
 
L
 
J
 
L
 
 in a set.
538 
 
V
 
H
 
 sequences from CD5
 
 
 
 and CD5
 
 
 
 peripheral B lym-
phocytes (10, 11) were downloaded from the public database.
These 538 sequences were compared independently with the
translated databases using tblastn on the BlastMachine at the
AMDeC Bioinformatics Core Facility at the Columbia Genome
Center at Columbia University.
 
Online Supplemental Material. 
 
Figs. S1–S7 depict detailed nu-
cleotide and amino acid sequence alignments of the junctional re-
gions and complete protein sequence alignments of the sequences
described here. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20040544/DC1.
 
Results and Discussion
 
Identification of Subgroups of B-CLL Patients with Highly
Restricted V
 
H
 
DJ
 
H
 
 Segments and Shared HCDR3 Configura-
tions. 
 
Each B-CLL–derived V
 
H
 
DJ
 
H
 
 sequence in our da-
tabase was compared with every B-CLL sequence in our
collection (
 
n
 
 
 
 
 
 255) as well as with those in the public Ig V
gene databases (
 
n
 
 
 
 
 
 197) using nucleotide and protein se-
quence BLAST. In addition, all available B-CLL H chain V
region sequences were phylogenetically grouped using the
ClustalW method; sequences that clustered together were
further analyzed for HCDR3 sequence similarity. These
screening methods identified sets of sequences (Table I, sets
I-Vb and Ve) consisting of the same 
 
IgV
 
H
 
 with highly simi-
lar HCDR3 resulting from identical 
 
D
 
 (when identifiable)
and 
 
J
 
H
 
 segment use, 
 
D
 
 segment reading frame, similar 
 
D
 
segment position relative to 
 
IgV
 
H
 
, and HCDR3 length, and
significant (
 
 
 
60%) amino acid sequence identity.
Three subsets of set V (Va, Vb, and Ve) contained se-
quences that used different 
 
IgV
 
H
 
 genes, but used the same
 
D
 
 and 
 
J
 
H
 
 segments, the same 
 
V
 
 
 
, and had highly similar
HCDR3 configurations. Therefore, we used the HCDR3
 
Table I.
 
Sets of B-CLL Cases That Share Ig V Region Genes
 
No. of sequences identified/source
B-CLL Most similar germline gene Median % mutation
Set Internal Public Non–B-CLL Isotype V
 
H
 
D; reading frame J
 
H
 
V
 
L
 
J
 
L
 
V
 
H
 
V
 
L
 
I3 2 1
 
a
 
IgM
 
 
 
1-69 3-16; philic 3
 
 
 
A27
 
 
 
1/
 
 
 
4/
 
 
 
5 0.0 0.0
II 3 0 0 IgM
 
 
 
1-69 2-2; phobic 6
 
 
 
L6
 
 
 
3 0.0 0.0
III 4 3 0 IgM
 
 
 
1-69 3-10; phobic 6
 
 
 
1-16
 
 
 
1/
 
 
 
3 0.0 0.2
IV 3 2 0 IgG
 
 
 
4-34 5-5; phobic 6
 
 
 
A17
 
 
 
1/
 
 
 
2 3.0 2.3
Va 4 2 1
 
b
 
IgM
 
 
 
1-02 6-19; stop 4
 
 
 
 O12/2
 
 
 
1/
 
 
 
2 0.0 0.0
Vb 2 3 0 IgM
 
 
 
1-03 6-19; stop 4   O12/2  1/ 2 0.8 0.0
Vc 1 0 0 IgM  1-18 6-19; stop 4   O12/2  1 1.4 0.0
Vd 0 2 0 IgM  1-46 6-19; stop 4 – – 0.0 –
Ve 2 5 0 IgM  5-51 6-19; stop 4   O12/2  2 0.0 0.0
aAnticardiolipin antibody.
bSplenic marginal zone lymphoma.Messmer et al. Brief Definitive Report 521
motif common to these three subsets to search public data-
bases for additional sequences with the same HCDR3 con-
figuration potentially associated with a different IgVH seg-
ment. This search was not restricted to B-CLL sequences.
The approach confirmed the previously identified subsets
and identified two additional subsets of set V (Vc and Vd).
The public database searches identified 21 VHDJH se-
quences, belonging to one of the five individual sets, bring-
ing the total number of sequences among these sets to 43.
Interestingly, only 2 of the 21 sequences culled from the
public databases were not derived from B-CLL cells. These
two were from an anticardiolipin antibody-producing B cell
(set I) and from a splenic marginal zone lymphoma (set Va).
This distribution of similar sequences is particularly striking
because, at the time of this search, the public databases con-
tained only 197 Ig H chain V region sequences from B-CLL
patients (excluding those from our laboratories) out of a total
of  8,500 H chain V region sequences (search of Entrez
with terms “human immunoglobulin heavy chain variable”
produced 8,874 hits in the nucleotide database and  6,183
hits in the protein database on 12/16/03).
Pairing Restricted VLJL Rearrangements with VHDJH Seg-
ments in Sets.  VLJL sequences corresponding to the shared
VHDJH of the five sets were available for most of our B-CLL
cases and for a few of those identified in the public data-
bases. Remarkably, the available IgVL were highly con-
served within the sets, and the corresponding JL were very
restricted (Table I and Table S1, available at http://www.
jem.org/cgi/content/full/jem.20040544/DC1). Four out
of the five sets with available L chains expressed the  
isotype.
IgV Gene Mutation Status and Isotype Restrictions of Individual
Sets.  Most of the IgVH sequences in each set differed by
 2.0% from the most similar germline gene, with the ex-
ception of set IV in which the median level of mutation
was 3.0%. Notably, the deduced protein structures in those
sequences that were considered “mutated” using the typical
2% threshold differed from the germline by relatively low
levels. Only one sequence, from set IV (Table S1, CLL
ID47), differed by  5% from its germline counterpart. The
corresponding IgVL in each set exhibited low levels of mu-
tation; in some cases, VL displayed  2.0% difference,
whereas  VH had  2% difference from the germline se-
quence (Table I and Table S1).
The H chain isotype was the same among members of a
set. All sets expressed IgM, except for set IV that consisted of
IgG  cases, similar to a patient group reported previously (9).
H and L CDR3 Characteristics of the Individual Sets.  We
identified trends in the chemical, structural, or functional na-
ture of the residues that comprise the H and L CDR3s, and
in particular their VH-D and D-JH junctions (Fig. 1). For ex-
ample, the D segments in the HCDR3s of these sets were
read in the hydrophobic and stop reading frames more often
than in normal (12) and B-CLL (13) cells. For all cases in set
V, the D6-19 segment is read in a nonproductive reading
frame (Table I). However, the germline stop codon, located
in the region of overlap with the terminal IgVH sequence,
was trimmed, allowing productive rearrangements with the
JH4 segment (Fig. S7, available at http://www.jem.org/cgi/
content/full/jem.20040544/DC1).
Also of note was the repeated occurrence of certain non-
germline encoded amino acids within D segments in some
of the sets. For example, in all members of set II, a change
to M is found at the 3  end of the D segment (Fig. S4, avail-
able at http://www.jem.org/cgi/content/full/jem.20040544/
DC1), a position that is not known to be polymorphic.
Figure 1. Sets of highly similar H and L CDRs among groups of B-CLL
patients. Translated CDR3 regions are shown for all sequences within a set.
Homology to the germline sequence is indicated by dots, and functionally
similar replacement amino acids are indicated in gray. Amino acid replace-
ments that may be attributed to known allelic differences are underlined.Multiple Distinct Sets of Stereotyped Antigen Receptors in B-CLL 522
Three out of seven sequences in set III had an R to Q
change within the D3-10 segment that is also not listed as
polymorphic (Fig. S5, available at http://www.jem.org/
cgi/content/full/jem.20040544/DC1). In four out of five
cases in set IV, P replaced A in the portion of HCDR3 en-
coded by the canonical D5-5 segment. Although this is
most likely a polymorphism of the D segment rather than
a common mutation, the last of the five sequences in this
set (CLL ID47) also deviates from the canonical D5-5
sequence at this codon, substituting a D (Fig. S6, available
at http://www.jem.org/cgi/content/full/jem.20040544/
DC1). Thus, even if these amino acid changes represent
polymorphisms, their relative consistency within each set
suggests a selection for these residues.
Members of several sets have common junctional residues
that were not templated by any known germline gene seg-
ments and, therefore, presumably arose from trimming and/
or addition during recombinational assembly. The sequences
in set I all contain a pair of Gs at the VH-D junction and an
N at the D-JH junction (Fig. 1 and Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20040544/DC1). A very
similar VH-D junctional finding exists in set II (Fig. 1 and
Fig. S4). All sequences in set IV contain an aromatic residue
at the VH-D and a pair of basic residues (R or K) at the D-JH
junction (Fig. 1 and Fig. S6).
Other trends in the composition of the H and L CDR3s
are found in the other sets. These and the fine details of the
nucleotide and amino acid sequences of the VHDJH and
VLJL junctions for each set are shown and discussed in the
online supplemental data (Figs. S3–S7).
Structural Similarities of the BCR among Members of the
Sets.  The deduced VHDJH and VLJL protein sequences for
each member of the stereotyped sets are presented in Figs.
S1 and S2 (available at http://www.jem.org/cgi/content/
full/jem.20040544/DC1). Because most members of the
sets use the same IgVH, primarily in an unmutated form, as-
sociated with the same D and JH segments and because these
rearrangements are virtually always paired with an identical
IgVL that is restricted in its linked JL, the primary structural
features of the entire BCR of each set are likely remarkably
similar. Furthermore, the amino acid sequences of HCDR1,
HCDR2, LCDR1, and LCDR2 of members of the individ-
ual sets are extremely similar, if not identical (e.g., sets I–III,
and the set V subsets). In set IV, some amino acid differences
exist in these regions due to somatic mutation.
These data indicate a much more marked constraint on
the primary structure of the BCR in B-CLL than appreci-
ated previously. They also indicate that this principle oc-
curs in a sizeable number of patients. Collectively,  12%
(31 out of 255: 22 from this work, 5 from our previous pa-
per [9], and 4 that match another described set [8, 10]) of
all of sequences in our internal laboratory B-CLL database
and  20% (27 out of 131) of those with unmutated IgV
belong to one out of the five stereotyped sets described
here or one out of the two aforementioned patient groups
(8–10). Approximately the same overall frequency ( 12%)
was encountered among the sequences from the public da-
tabases (21 out of 197), although the proportion of the
public B-CLL sequences that are unmutated was not deter-
mined. Most of the rearrangements in these sets lack or
have few somatic mutations, and even those whose VH sur-
pass the 2% threshold commonly used as the criterion to
define significant IgV gene mutations (4, 5) are only slightly
above that level. This suggests that restricted BCR struc-
ture is primarily a feature of those patients with the worse
clinical course and outcome (1, 2). It appears that one out
of five B-CLL cases with unmutated BCRs fit into one of
these defined sets. Additional sets will likely be uncovered
as more Ig V region sequences are defined in B-CLL, and
all unmutated cases may be similar to one of a discrete
number of archetypal sets. Although sets I–III use unmu-
tated 1-69, they differ from previously described 1-69–
expressing B-CLL cases that have restrictions in specific D
and JH segments associations (4, 6). These differences in-
clude JH (set I, JH3 vs. JH6), D (set II, D2 vs. D3 family and
V L6 with an extremely short LCDR3), and L chain (set
III,   vs.  ) gene use.
Initial studies that considered only IgVH or VHDJH (4–6,
14) pointed toward limited structural diversity in the anti-
gen-binding sites of B-CLL. However, our current results
are much more striking because of the remarkable similarity
of the sequences within a set and the virtual mathematic im-
possibility that this similarity arose by chance. If gene seg-
ment use in B-CLL was random, the probability of finding
the same combination of VHDJH and VLJL segments in inde-
pendent leukemic (or normal) B cells would be  10 6.
Therefore, one would not expect to identify two B-CLL
patients with BCRs comprised of the same VHDJH/VLJL un-
til  106 cases were analyzed. This calculation is conserva-
tive because it does not account for diversity at the VH-D,
D-JH, and VL-JL junctions that can be quite extensive (po-
tentially exceeding 10 9 and reaching 10 12), although re-
ceptor editing and revision could limit these possibilities
somewhat. Nevertheless, the level and frequency of BCR
structural restriction in clusters of patients reported here is
extraordinary and appears to be higher than any other B or
T cell lymphoproliferative disorder reported to date.
Finding similar Ig H chain V region sequences by homol-
ogy searches of the public databases is not, in itself, com-
pletely surprising because some IgVH are expressed in a bi-
ased fashion and  6,600 different VH-D-JH combinations
can occur. Because the databases contain more than that
number of Ig H chain V region sequences, identifying the
same recombined gene segments is not improbable. When
we analyzed 538 CD5  and CD5  B cell–derived H chain
V region sequences, we identified many pairs of similar se-
quences and some groups of similar sequences. However,
these groups derived from B cells of diverse sources, as
would be expected if the similarities were the product of
random chance. In contrast, the similarity to a given B-CLL–
derived sequence detected in our database comparisons arose
almost exclusively from other B-CLL sequences (19/21) or
other lymphoproliferative disorders (1/21), even though the
entire database was searched. Only one identified sequenceMessmer et al. Brief Definitive Report 523
was from a non–B-CLL clone, one that coded an autoanti-
body (Table I and Table S1). Although the proper normal B
cell repertoire against which B-CLL clones should be com-
pared remains an open question (3), these results demon-
strate that sequence sets of restricted cellular origin are not a
generalized phenomenon in the public database.
Therefore, the development of B-CLL must involve B
cell clones with restricted IgV and/or BCR structure. Al-
though it seems unlikely that the expression of particular
BCR gene combinations could be the sole promoting fac-
tor for leukemogenesis, a strong inherent bias in gene seg-
ment association and VHDJH/VLJL pairing in the B cell
population that gives rise to B-CLL cannot be formally ex-
cluded, especially because the cell of origin for B-CLL is
still uncertain (3). Although evidence exists in mice for bi-
ases in the recombination of particular Ig V gene segments
before antigen experience (15), the extent of restriction
imposed by recombination biases at both the H and L chain
V gene loci in those instances, especially at the V-(D)-J
junctions, are not as severe as in the sets described here. To
our knowledge, there is no known subpopulation of hu-
man B cells in which the frequency of similar rearrange-
ments, independent of antigen selection, is as great as
among these B-CLL cases.
Therefore, antigen selection probably has a major restric-
tive influence on the transformation of a normal B lym-
phocyte to a B-CLL cell. A simple model would postulate
that the transforming event is coupled with antigen speci-
ficity; i.e., an individual B lymphocyte from a highly di-
verse population could bind and internalize a transforming
agent (e.g., virus) via its BCR. Although this seems un-
likely, such a mechanism has been implied for B-CLL (16).
Alternatively, antigen could be a promoting factor for
transformation, selecting specific clones for expansion from
an initially diverse population of B lymphocytes and foster-
ing their development to and in the transformed state (3).
This would be the case if the B-CLL–susceptible cell popu-
lation were preselected for antigen reactivity and, there-
fore, BCR structure, by exposure to distinct antigens or
classes of antigens during their development. These clones
could differ among patients, especially if the selecting anti-
gens were foreign or autologous and possibly polymorphic.
From within these clonal expansions, one member could
develop an initial transforming lesion that would promul-
gate the leukemogenic cascade independent of antigen.
Finally, the initial transforming events could occur at
random within a diverse B cell population or a previously
antigen-selected population, and the subsequent nurturing
of the transformed clone to clinical B-CLL could require
ongoing BCR engagement by antigen (3). Recently, clonal
expansions of B cells with phenotypic characteristics of
B-CLL were found in normal elderly individuals (17, 18).
The clinical relevance of these clones is not established.
However, they may represent clones that have some of the
genetic lesions of B-CLL, but lack BCR specificities that
would result in sufficient ongoing stimulus to mature them
into clinical B-CLL.
The remarkable protein similarity of the entire BCR
among members of each set (Figs. S1 and S2) suggests that
they could recognize the same or similar antigens. Although
the nature of the antigens cannot be directly deduced from
the Ig sequences presented here, there are several reasons to
suspect that they are autoantigens or carbohydrates possibly
derived from bacterial or viral coats, or a combination of
the two.
VH1-69 (sets I–III) and VH3-21 (previously described set
[8, 10]) are enriched among rheumatoid factors (19, 20).
VH4-34 (set IV) is used in every case of monoclonal cold
agglutinin disease (21) and in autoimmune conditions. In-
deed, the inherent autoreactivity of this VH segment elicits
a major inhibitory process by the immune system that
keeps 4-34  B cells from diversifying into high affinity, iso-
type-switched B cells (22). The anticardiolipin antibody
identified as a member of set I implies that the other mem-
bers of that set may be specific for cardiolipin or DNA be-
cause some antibodies to the former react with the latter
(23). In addition, restricted VHDJH and/or VLJL gene seg-
ments are features of B cells that produce anticarbohydrate
mAb in human (24) and mouse (25).
Characteristic junctional residues are also a feature of an-
ticarbohydrate mAb and autoantibodies and basic junctional
residues, as seen in sets I, IV, and Ve (Fig. 1 and Fig. S1), of-
ten indicate reactivity with acidic targets such as DNA (26).
The synthesis of autoreactive Ig/BCR molecules by many
B-CLL clones (27, 28) supports a link between the unique
BCR structural features of these sets and autoantibodies.
The non–B-CLL Ig sequences that matched these B-CLL
stereotypes may give insight into the identity of the B-CLL
progenitor cells. One of those two was derived from a
splenic marginal zone lymphoma (Table S1, set Va), and the
other was derived from an autoantibody-producing B cell
(Table S1, set I). Interestingly, normal MZ B cells produce
mAb that can recognize thymus-independent type II anti-
gens and autoantigens (29). In addition, the Ig V region rep-
ertoire of murine MZ B cells is very restricted in gene seg-
ment use and structure that requires intact BCR signal
transduction to develop (30). MZ B cells appear to be pro-
genitors for gastric MALT lymphoma (31) and have been
proposed as precursors of B-CLL cells (3). If one infers
common antigenic reactivity based on the similar sequences
within a set, a significant fraction of B-CLL cases, and in
particular those with unmutated IgV genes, could produce
mAb that recognize one of a limited, discrete array of anti-
gens or epitopes. With such an interpretation, some B-CLL
cases may resemble gastric MALT lymphoma regarding the
role of antigenic drive (in that instance, Helicobacter pylori) in
the promotion of malignancy. The stereotyped Ig molecules
reported here might be valuable probes to identify antigens
that drive the leukemogenic process in B-CLL.
Finally, these sets of stereotyped Ig molecules may serve
as therapeutic targets on B-CLL cells. A conceptual draw-
back to targeting the BCR as a tumor-specific antigen has
been the apparent need to create an individualized reagent
for each patient. However, because our data indicate thatMultiple Distinct Sets of Stereotyped Antigen Receptors in B-CLL 524
there is potentially extensive overlap in BCR structure and
specificities among groups of B-CLL cases, this approach
may be far less daunting. Indeed, because  20% of the
cases with unmutated IgVH genes fall into one of these sets,
such targeting might be most effective in those cases that
have the worst prognosis, are least responsive to therapy,
and have the most aggressive clinical courses (1, 2).
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